News

Statement from the Canadian Generic Pharmaceutical Association Regarding Windsor-Detroit Border Announcement

Challenge is for Canadian private and public payers to increase use of generic equivalents

Toronto, June 15, 2012 – Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), made the following statement on today’s announcement regarding construction of a second bridge at the Windsor-Detroit border:

“Today’s announcement by Prime Minister Harper and Michigan Governor Rick Snyder of the planned construction of a second bridge between Windsor and Detroit is a critical step forward in ensuring faster and more reliable border crossings for Canada’s value-added manufacturers.

The Ambassador Bridge is currently the only fully commercial crossing in the region and handles 25 percent of all trade between Canada and the United States. Bottlenecks at the Ambassador Bridge border crossing have been a long frustration for Canada’s generic pharmaceutical industry and manufacturers in other industrial sectors. Traffic demands on this crossing are expected to rise considerably in the coming years.

Generic pharmaceutical companies operate most of the domestic manufacturing capacity for pharmaceuticals in Canada, and export more than 40 percent of Made-In-Canada generic pharmaceutical products. The United States comprises 30 percent of the global market for pharmaceuticals, and is the single largest and most important export destination for Canadian-made generic drugs.

Efforts that will ultimately improve the speed at which our value-added generic pharmaceutical products can enter the United States through this important trade corridor are welcomed by Canada’s generic pharmaceutical manufacturers, and we congratulate Prime Minister Harper and Michigan Governor Rick Snyder on the occasion of this important milestone.”

About the Canadian Generic Pharmaceutical Association
The Canadian Generic Pharmaceutical Association (CGPA) represents Canada’s generic pharmaceutical industry. The industry plays an important role in controlling health-care costs in Canada. Generic drugs are dispensed to more than 60 per cent of all prescriptions but account for only less than 24 percent of the $22-billion Canadians spend annually on prescription medicines.

For more information, please contact:

Jeff Connell
Vice President, Corporate Affairs
Canadian Generic Pharmaceutical Association (CGPA)
Tel: (416) 223-2333
Mobile: (647) 274-3379
Email: jeff@canadiangenerics.ca
Website: www.canadiangenerics.ca